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I
n this issue of the Journal, Dr. Berg and colleagues present
their views on the NIH grant application review process in
their article entitled, “Demystifying the NIH Grant Application
Process”.
1 Having served at the NIH for a couple of years, I can
attest that they have summarized the process with some
accuracy and overall offer good advice and counsel. However,
they have missed a few of the nuances to the process that I
believe represent pieces of knowledge that are important for
the individual who aspires to a career as an independent
clinical investigator. Now here is the rest of the story.
First and foremost, one should keep in mind that each
institute or center (referred to as IC by those at NIH) has its
own culture or approach to the business of funding good
science. So, if you are familiar with the modus operandi of 1 IC,
you only know 1 IC.
Second, the NIH has 3 general mechanisms for carrying out
its mission to improve the nation’s health. Berg et al. discuss
the first of these, which is the grant award where the
investigator specifies what is to be achieved and how, and the
NIH is essentially a patron, providing the funds (to those
applications judged scientifically meritorious).
1 Then, there are
contracts under which the NIH specifies what is to be achieved
and how, and investigators “bid” on the project. Finally, there
is the lesser-known cooperative agreement where an IC is a
partner with the investigator in designing and conducting a
project. Cooperative agreements—funded under the U mecha-
nism—tend to develop out of conversations between investiga-
tors and IC program officials and involve projects with aims for
which an IC has a vested interest in seeing achieved. These are
not entered into readily and, although a partnership, the
project must still pass rigorous peer review to ensure its
scientific merit. Still, a cooperative agreement is worth explor-
ing for projects that are highly aligned with an IC’s mission and
with potential to significantly improve the nation’s health.
It is also worth knowing that program announcements (PA’s)
can be of 3 types: PA, PAR, and PAS. Berg et al. discuss the PA.
1
The PAR involves scientific review within the soliciting IC
versus review by one of the integrated review groups (IRGs) at
the Center for Scientific Review. Some believe these “in-house”
reviews are more advantageous to the investigator. From my
experience, whereas there may be fewer applications consid-
ered, the review is no less rigorous. The review panel, though,
is comprised of those with considerable expertise in the area of
the PAR so they understand the science very well. Whether this
is an advantage is hard to say. The PAS has set aside funds,
that is, funds dedicated to support scientifically meritorious
applications solicited by the PAS. This arrangement clearly is
advantageous to the applicant.
Review, whether of grant applications or manuscripts, is an
inherently conservative process. I have served on review panels
and, as a NIH program officer, watched review panels in action.
The young investigator who has an anemic record of funded
grants and published articles is at a distinct disadvantage. The
NIH is well aware of the unequal playing field faced by the new
investigator, and has tried to correct it. New investigator status is
indicated on the application form and scientific review adminis-
trators (SRAs)—the individuals legally responsible for an impar-
tial review process—remind panels when it is noted that an
investigator is new that the application needs to be reviewed with
this in mind. In my personal experience, I have rarely seen the
new investigator accorded much leeway: the application is
typically judged to the same level of scientific rigor accorded
established investigators. Be that as it may, the new investigator
can enhance their likelihood of success by good grantsmanship.
To paraphrase Louis Pasteur, “NIH favors only the prepared
grant application”. By prepared, I refer to more than an
application that conforms to the guidelines, although that is
essential if you want your grant application reviewed. I also
mean a narrative in which the objectives flow logically from the
current gaps in knowledge and the study design and method-
ology are appropriate to answering the objectives. This is what
is known as good grantsmanship and are the typical points of
trouble for the novice grant writer. “Unfocused” grant applica-
tions invariably fail to propose methods that are appropriate to
answering the objectives or fail to adequately describe the
methods. It is not wasted effort to describe the rationale for
selecting among available alternative approaches.
I also want to emphasize several other components of good
grantsmanship. First, the NIH is interested in topics that have
high clinical relevance. Applications where the clinical rele-
vance is obvious and clearly delineated do better in review.
Second, projects that are concise do better in review. If the
summary statement describes your proposal as “ambitious’,
you have bitten off more than you can proverbially chew, at
least as adjudicated by the reviewers. Third, applications with
pilot data that provide direct support for the hypotheses and
objectives do better. Of the last 3 points, this latter one is most
important and should never be neglected. Because review is a Published online September 25, 2007
1628conservative process, supporting evidence can help convince
the reviewers that the project is meritorious.
Because of the odds against them, the novice clinical investi-
gator must be persistent in seeking funding. However, the
applicant should not write the grant application with the view
that “No one ever gets funded the first time” or “I’ll benefit from
review”. Write it to succeed the first time. As noted, poor
grantsmanship is often thereason for failure.Again,the common
errors are trying to do too much, failure to explicitly and clearly
link the study objectives to the methodological approach, and
failure to provide sufficient detail on the methods.
If your application fails to pass scientific review, a careful
read of the review will generally inform you as to how to amend
the application. The key operative is careful. Summary state-
ments are often difficult to decipher. For example, poorly
written grants may receive relatively few comments as there
are so many flaws that it is not worth the reviewers’ time and
effort to identify them all. The ability to read between the lines
is a skill that will assist the novice grant writer in achieving
success on subsequent attempts.
In the Art of War, it states that if you know yourself and
know your enemy, you will invariably be victorious.
2 It is worth
keeping in mind the purpose of NIH and our purpose as
clinical investigators. The fundamental raison d’etre for NIH is
to improve the nation’s health. Whereas it may seem that there
is a bias at NIH toward studies that address the mechanism of
disease, the NIH ROADMAP initiative is a sincere attempt to
rebalance funding priorities to give higher priority to projects
that are not mechanistic in focus but seek to solve questions
facing the clinician in everyday practice. It is a healthy trend.
For the clinical investigator, the motivation should be to
engage in studies that have high probability of yielding
knowledge that will have a more direct and immediate impact
on the individual’s health through improvement in health
behaviors and health care practices. There are many reasons
a clinician becomes a clinical investigator; I hope the noble goal
of improving health and health care would be the foremost
impetus for embarking on this road.
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